英矽智能与武田制药达成超6亿美元战略合作,以生成式AI赋能多领域药物发现 (IMAGE) InSilico Medicine Caption 根据协议,英矽智能将主导AI驱动的药物发现工作,负责设计并筛选出符合预设科学标准及早期开发标准的候选分子;武田制药则将发挥其强大的全球开发能力,推进相关候选药物的临床验证。 Credit 英矽智能 Usage Restrictions None License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.